| Literature DB >> 27895858 |
Ghazal Naderi1, Fakhri Haghi1, Habib Zeighami1, Fatemeh Hemati1, Neda Masoumian2.
Abstract
AIM: This case-control study investigated the various PAI markers, phylogenetic groups and antimicrobial susceptibility among DEC and commensal E. coli isolates.Entities:
Keywords: Child; Developing countries; Diarrhea; Escherichia coli; Pathogenicity Island
Year: 2016 PMID: 27895858 PMCID: PMC5118857
Source DB: PubMed Journal: Gastroenterol Hepatol Bed Bench ISSN: 2008-2258
Primers used in this study
| PAIs | Marker gene | Oligonucleotide sequence (5ʹ-3ʹ) | Product size bp | Ref. |
|---|---|---|---|---|
| She |
| fp: ATTCTTCTGGCTGGCATTCC | 606 | 29 |
| HPI |
| fp: AAGGATTCGCTGTTACCGGAC | 287 | 29 |
| LEE |
| fp: GACCCGGCACAAGCATAAGC | 384 | 29 |
| SHI-2 |
| fp: GGCTGGACATCATGGGAACTGG | 301 | 29 |
| Tia |
| fp:CGGGATCCGATGAGAGCAAAACAGGCTT | 756 | 29 |
| EspC |
| fp: GCTCAACTAAATATTGATAATGTATG | 453 | 29 |
| O-islands |
| fp: GAACAAAGAACATTTTCACCAGTTC | 521 | 29 |
| ChuA |
| fp: GACGAACCAACGGTCAGGAT | 279 | 17 |
| YjaA |
| fp: TGAAGTGTCAGGAGACGCTG | 211 | 17 |
| TspE4C2 |
| fp: GAGTAATGTCGGGGCATTCA | 152 | 17 |
Distribution of PAIs among 50 commensal and 136 diarrheagenic isolates of E. coli
| Pathogenicity island | No. (%) of isolates carrying PAIs |
| Total ( | |
|---|---|---|---|---|
| DEC ( | Commensal ( | |||
| HPI | 125 (91.9%) | 34 (68%) | <0.0001 | 159 (85.5%) |
| SHI-2 | 109 (80.1%) | 7 (14%) | <0.0001 | 116 (62.4%) |
|
| 112 (82.3%) | 9 (18%) | <0.0001 | 121 (65%) |
| LEE | 108 (79.4%) | 6 (12%) | <0.0001 | 114 (61.3%) |
| EspC | 11 (8.1%) | 4 (8%) | 0.984 | 15 (8%) |
| Tia | 8 (5.9%) | 2 (4%) | 0.616 | 10 (5.4%) |
| O-island | 5 (3.7%) | 1 (2%) | 0.569 | 6 (3.2%) |
Specific PAI combinations among the 141 Escherichia coli isolates (commensal and diarrheagenic) carrying more than one PAI
| No. PAIs | PAI Combinations | No. (%) PAIs in DEC (n=136) | No. (%) PAIs in commensal (n=50) | Total No. (%) |
|---|---|---|---|---|
| 2 PAIs | SHI-2 + HPI | 3 (2.2) | 2(4) | 17 (9.1) |
| She + HPI | 2(1.4) | 4 (8) | ||
| LEE + HPI | 2 (1.4) | - | ||
| She + SHI-2 | 1 (0.7) | - | ||
| LEE + She | 2 (1.4) | - | ||
| LEE + O-islands | 1 (0.7) | - | ||
| 3 PAIs | LEE + SHI-2+ HPI | 10 (7.3) | - | 38 (20.4) |
| LEE + She+ HPI | 10 (7.3) | - | ||
| SHI-2 + EspC+ HPI | 1 (0.7) | - | ||
| EspC + O-islands + HPI | - | 1 (2) | ||
| She + SHI-2 + HPI | 15 (11) | 1 (2) | ||
| 4 PAIs | LEE + She + SHI-2+ HPI | 68 (50) | 2 (4) | 76 (40.8) |
| She + EspC + Tia + HPI | 1 (0.7) | - | ||
| LEE +She + EspC + HPI | 1 (0.7) | - | ||
| LEE + She + O-islands + HPI | 1 (0.7) | - | ||
| LEE + She + Tia + HPI | 1 (0.7) | - | ||
| She + SHI-2 + O-islands + HPI | 1 (0.7) | - | ||
| LEE + SHI-2 + EspC + HPI | 1 (0.7) | - | ||
| 5 PAIs | LEE + She + SHI-2 + EspC + HPI | 2 (1.4) | 1 (2) | 8 (4.3) |
| LEE + She + SHI-2 + Tia + HPI | 2 (1.4) | 1 (2) | ||
| LEE + SHI-2 + EspC + Tia+ HPI | 1 (0.7) | - | ||
| LEE + She + SHI-2 + O-islands + HPI | 1 (0.7) | - | ||
| 6 PAIs | LEE + She + SHI-2 + Tia + O-islands + HPI | 1 (0.7) | - | 2 (1) |
| LEE + She + SHI-2 + Tia + EspC + HPI | 1 (0.7) | - |
Comparison of phylogenetic groups between DEC and commensal isolates
| Group | DEC (n= 136) | Commensal (n= 50) |
|
|---|---|---|---|
| A | 13 (9.5%) | 19 (38%) | 0.000 |
| B1 | 5 (3.7%) | 15 (30%) | 0.000 |
| B2 | 60 (44.1%) | 9 (18%) | 0.001 |
| D | 58 (42.7%) | 7 (14%) | 0.000 |
Antimicrobial drug resistance patterns among 186 diarrheagenic and commensal E. coli isolates
| Antimicrobial agents | Commensal | Diarrheagenic | Total (n=186) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| R(%) I(%) S(%) | R(%) I(%) S(%) | R(%) I (%) S(%) | |||||||
| Amoxicillin | 31(16.7) | 0 | 19(10.2) | 105(56.4) | 5(2.7) | 26(14) | 136(73.1) | 5(2.7) | 45(24.2) |
| Cefoxitine | 8(4.3) | 0 | 42(22.6) | 21(11.3) | 0 | 115(61.8) | 29(15.6) | 0 | 157(84.4) |
| Ceftazidime | 12(6.5) | 2(1.1) | 36(19.3) | 57(30.7) | 4(2.1) | 75(40.3) | 69(37.1) | 6(3.2) | 111(59.7) |
| Cefotaxime | 15(8.1) | 3(1.6) | 32(17.2) | 56(30.1) | 4(2.1) | 76(40.9) | 71(38.2) | 7(3.8) | 108(58) |
| Cefepime | 5(2.7) | 2(1.1) | 43(23.1) | 48(25.8) | 10(5.4) | 78(41.9) | 53(28.5) | 12(6.4) | 121(65.1) |
| Co-amoxiclav | 25(13.4) | 1(0.5) | 24(12.9) | 83(44.7) | 0 | 53(28.5) | 108(58.1) | 1(0.5) | 77(41.4) |
| Imipenem | 0 | 0 | 50(26.9) | 4 (2.1) | 0 | 132(71) | 4(2.1) | 0 | 182(97.9) |
| Azteronam | 22(11.8) | 5(2.7) | 23(12.4) | 78(41.9) | 11(5.9) | 47(25.3) | 100(53.8) | 16(8.6) | 70(37.6) |
| Gentamicin | 12(6.4) | 5(2.7) | 33(17.7) | 50(26.9) | 18(9.7) | 68(36.6) | 62(33.3) | 23(12.4) | 101(54.3) |
| Tetracycline | 13(7) | 1(0.5) | 36(19.4) | 74(39.8) | 1(0.5) | 61(32.8) | 87(46.8) | 2(1.1) | 97(52.1) |
| Co-trimoxazole | 20(10.8) | 3(1.6) | 27(14.5) | 72(38.7) | 3(1.6) | 61(32.8) | 92(49.5) | 6(3.2) | 88(47.3) |
| Amikacin | 5(2.7) | 1(0.5) | 44(23.7) | 35(18.8) | 11(5.9) | 90(48.4) | 40(21.5) | 12(6.5) | 134(72) |
| Ciprofloxacin | 8(4.3) | 3(1.6) | 39(21) | 43(23.1) | 3(1.6) | 90(48.4) | 51(27.4%) | 6(3.2) | 129(69.4) |
S: susceptible; R: resistant; I: intermediate
% shown for DEC or commensal isolates is % compared to the total number of isolates